A Phase 2/3 interventional study of Placebo and Guselkumab in Ulcerative Colitis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 392 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 2/3, reaches primary completion later than 0 of the 20 other live ones, and was the 22nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 18 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,064 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 205 across the 28 interventional studies, 200 across the 15 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
4 of the studies in Colitis, Ulcerative by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
Drug: Guselkumab
Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
Drug: Guselkumab
Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
Drug: Placebo
Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
Drug: Guselkumab
Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
Drug: Placebo
Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
Drug: Guselkumab
Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
Drug: Guselkumab
Participants will receive matching placebo SC q4w.
Drug: Placebo
Participants will receive matching placebo IV or SC.
Participants will receive guselkumab IV or SC.
Induction Study 1: Percentage of Participants With Clinical Response at Week I-12
Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12
Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.
Time frame: At Week I-12
Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44
Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-1 and IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for randomized arms only.
Time frame: At Week M-44
Induction Study 1: Percentage of Participants With Clinical Remission at Week I-12
Time frame: At Week I-12
Induction Study 1: Percentage of Participants With Symptomatic Remission at Week I-12
Time frame: At Week I-12
Induction Study 1: Percentage of Participants With Endoscopic Healing at Week I-12
Time frame: At Week I-12
Induction Study 1: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12
Time frame: At Week I-12
Induction Study 1: Percentage of Participants With Endoscopic Normalization at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Endoscopic Healing at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Clinical Response at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-4
Time frame: At Week I-4
Induction Study 2: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Fatigue Response at Week I-12
Time frame: At Week I-12
Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-2
Time frame: At Week I-2
Induction Study 2: Percentage of Participants With Endoscopic Normalization at Week I-12
Time frame: At Week I-12
Maintenance Study: Percentage of Participants With Symptomatic Remission at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Endoscopic Healing at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Corticosteroid-free Clinical Remission at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Clinical Response at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With IBDQ Remission at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Fatigue Response at Week M-44
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Clinical Remission at Week 44 Among the Participants Who Had Achieved Clinical Remission at Maintenance Baseline
Time frame: At Week M-44
Maintenance Study: Percentage of Participants With Endoscopic Normalization at Week M-44
Time frame: At Week M-44
This study consisted of 3 separate studies: induction study 1 (IS-1), induction study 2 (IS-2) and maintenance study (MS). In IS-1 and IS-2, participants with modified Mayo score (MMS) of 4 to 9 at baseline (Induction Week 0 \[Week I-0\]) with inadequate response or failed to tolerate conventional or advanced therapy were enrolled.
| Milestone | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w | MS: Nonrandomized: Placebo SC q4w | MS: Nonrandomized: Guselkumab 200 mg SC q4w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 109 | 108 | 111 | 0 | 0 | 296 | 440 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 108 | 108 | 111 | 0 | 0 | 295 | 440 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Full analysis set (fas) | 105 | 101 | 107 | 0 | 0 | 280 | 421 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fas participants who enrolled into ms | 32 | 60 | 65 | 0 | 0 | 82 | 274 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 103 | 105 | 110 | 0 | 0 | 270 | 422 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 1 | 0 | 0 | 26 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 | 0 | 9 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 0 | 12 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w | MS: Nonrandomized: Placebo SC q4w | MS: Nonrandomized: Guselkumab 200 mg SC q4w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 67 | 79 | 0 | 0 | 172 | 129 | 0 | 0 | 0 | 0 | 0 |
| Is-1: period 1 guselkumab 200 mg iv non responders | 0 | 0 | 0 | 0 | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Is-1: period 1 guselkumab 400 mg iv non responders | 0 | 0 | 0 | 0 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 0 | 0 | 0 | 67 | 79 | 0 | 0 | 171 | 129 | 0 | 0 | 0 | 0 | 0 |
| Fas participants who enrolled into ms | 0 | 0 | 0 | 49 | 49 | 0 | 0 | 120 | 74 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 64 | 77 | 0 | 0 | 162 | 117 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 10 | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Crossed over but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w | MS: Nonrandomized: Placebo SC q4w | MS: Nonrandomized: Guselkumab 200 mg SC q4w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 201 | 199 | 199 | 122 | 125 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 201 | 199 | 199 | 122 | 125 |
| Full analysis set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 190 | 188 | 190 | 114 | 123 |
| Safety all randomized and treated analysis set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 203 | 197 | 199 | 0 | 0 |
| Dose adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75 | 23 | 31 | 0 | 0 |
| Safety all nonrandomized and treated analysis set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 122 | 125 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 173 | 177 | 176 | 95 | 107 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 22 | 23 | 27 | 18 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 9 | 10 | 11 | 5 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 1 | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 7 | 6 | 5 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Withdrew: Site closure in ukraine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
Clinical response was defined as a decrease from induction baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1 point decrease from baseline (Week 0 of IS-1) in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.
| Percentage of participants | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 |
|---|---|---|---|
| Induction Study 1: Percentage of Participants With Clinical Response at Week I-12 | 27.6 | 61.4 | 60.7 |
Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for specified arms only.
| Percentage of participants | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 |
|---|---|---|
| Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12 | 7.9 (4.7 to 11.0) | 22.6 (18.6 to 26.6) |
Clinical remission was based on the modified Mayo score. Clinical remission was defined as Mayo stool frequency subscore of 0 or 1 and not increased from baseline (Week 0 of IS-1 and IS-2), a Mayo rectal bleeding subscore of 0, and Mayo endoscopic subscore of 0 or 1 with no friability. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. This outcome measure was planned to be analyzed for randomized arms only.
| Percentage of participants | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w |
|---|---|---|---|
| Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44 | 18.9 (13.4 to 24.5) | 45.2 (38.1 to 52.3) | 50.0 (42.9 to 57.1) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over IS-1 and 2 Period 1: From Week I-0 to Week I-12; IS-1 and 2 Period 2: From Week I-12 to 12 weeks after last dose of study drug (up to 32 weeks); MS: from Week M-0 up to Week M-44. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | 0/109 (0%) | 7/108 (6.5%) | 49/108 (45.4%) |
| IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | 0/108 (0%) | 1/108 (0.9%) | 33/108 (30.6%) |
| IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | 0/111 (0%) | 3/111 (2.7%) | 38/111 (34.2%) |
| IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | 0/67 (0%) | 2/67 (3%) | 17/67 (25.4%) |
| IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | 0/79 (0%) | 3/79 (3.8%) | 15/79 (19%) |
| IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | 2/296 (0.7%) | 21/295 (7.1%) | 88/295 (29.8%) |
| IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | 1/440 (0.2%) | 13/440 (3%) | 118/440 (26.8%) |
| IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | 0/172 (0%) | 4/171 (2.3%) | 38/171 (22.2%) |
| IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | 0/129 (0%) | 3/129 (2.3%) | 37/129 (28.7%) |
| MS: Randomized: Placebo SC Every 4 Weeks (q4w) | 0/203 (0%) | 3/203 (1.5%) | 112/203 (55.2%) |
| MS: Randomized: Guselkumab 100 mg SC q8w | 0/197 (0%) | 5/197 (2.5%) | 93/197 (47.2%) |
| MS: Randomized: Guselkumab 200 mg SC q4w | 0/199 (0%) | 12/199 (6%) | 109/199 (54.8%) |
| MS: Nonrandomized: Placebo SC q4w | 0/122 (0%) | 13/122 (10.7%) | 69/122 (56.6%) |
| MS: Nonrandomized: Guselkumab 200 mg SC q4w | 0/125 (0%) | 7/125 (5.6%) | 76/125 (60.8%) |
| MS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4w | 0/75 (0%) | 2/75 (2.7%) | 28/75 (37.3%) |
| MS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4w | 0/23 (0%) | 1/23 (4.3%) | 14/23 (60.9%) |
| MS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w | 0/31 (0%) | 2/31 (6.5%) | 20/31 (64.5%) |
| Event | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w | MS: Nonrandomized: Placebo SC q4w | MS: Nonrandomized: Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 4/108 | 0/108 | 1/111 | 1/67 | 2/79 | 15/295 | 6/440 | 1/171 | 1/129 | 1/203 | 1/197 | 1/199 | 2/122 | 2/125 | 1/75 | 0/23 | 1/31 |
| Anal FistulaGastrointestinal disorders | 0/108 | 0/108 | 0/111 | 0/67 | 0/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 1/122 | 0/125 | 0/75 | 1/23 | 0/31 |
| Anal AbscessInfections and infestations | 0/108 | 0/108 | 0/111 | 0/67 | 0/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 1/122 | 0/125 | 0/75 | 1/23 | 0/31 |
| Adenovirus InfectionInfections and infestations | 0/108 | 0/108 | 0/111 | 0/67 | 0/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 0/75 | 0/23 | 1/31 |
| Herpes ZosterInfections and infestations | 0/108 | 0/108 | 0/111 | 1/67 | 0/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 0/75 | 0/23 | 0/31 |
| AnaemiaBlood and lymphatic system disorders | 0/108 | 1/108 | 1/111 | 0/67 | 1/79 | 1/295 | 1/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 1/75 | 0/23 | 0/31 |
| Acute AbdomenGastrointestinal disorders | 0/108 | 0/108 | 0/111 | 0/67 | 1/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 0/75 | 0/23 | 0/31 |
| PyrexiaGeneral disorders | 0/108 | 0/108 | 0/111 | 0/67 | 1/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 0/75 | 0/23 | 0/31 |
| Covid-19Infections and infestations | 0/108 | 0/108 | 0/111 | 0/67 | 1/79 | 0/295 | 0/440 | 1/171 | 0/129 | 0/203 | 0/197 | 0/199 | 1/122 | 0/125 | 0/75 | 0/23 | 0/31 |
| HypoproteinaemiaMetabolism and nutrition disorders | 0/108 | 0/108 | 0/111 | 0/67 | 1/79 | 0/295 | 0/440 | 0/171 | 0/129 | 0/203 | 0/197 | 0/199 | 0/122 | 0/125 | 0/75 | 0/23 | 0/31 |
| Event | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-1: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 2: Guselkumab 200 mg IV at Weeks I-12, I-16 and I-20 | IS-2: Period 2: Guselkumab 200 mg SC at Weeks I-12, I-16 and I-20 | MS: Randomized: Placebo SC Every 4 Weeks (q4w) | MS: Randomized: Guselkumab 100 mg SC q8w | MS: Randomized: Guselkumab 200 mg SC q4w | MS: Nonrandomized: Placebo SC q4w | MS: Nonrandomized: Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Placebo SC q4w to Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Guselkumab 100 mg SC q8w to Guselkumab 200 mg SC q4w | MS: Dose Adjustment: Guselkumab 200 mg SC q4w to Guselkumab 200 mg SC q4w |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 3/108 | 1/108 | 3/111 | 2/67 | 3/79 | 12/295 | 5/440 | 7/171 | 7/129 | 59/203 | 20/197 | 26/199 | 26/122 | 21/125 | 7/75 | 2/23 | 5/31 |
| Covid-19Infections and infestations | 5/108 | 6/108 | 2/111 | 1/67 | 1/79 | 13/295 | 22/440 | 13/171 | 9/129 | 28/203 | 28/197 | 20/199 | 19/122 | 23/125 | 5/75 | 3/23 | 2/31 |
| AnaemiaBlood and lymphatic system disorders | 11/108 | 8/108 | 9/111 | 4/67 | 2/79 | 20/295 | 22/440 | 4/171 | 6/129 | 5/203 | 5/197 | 6/199 | 5/122 | 6/125 | 3/75 | 2/23 | 0/31 |
| HaemorrhoidsGastrointestinal disorders | 1/108 | 0/108 | 2/111 | 0/67 | 0/79 | 1/295 | 4/440 | 1/171 | 1/129 | 1/203 | 1/197 | 0/199 | 3/122 | 2/125 | 0/75 | 2/23 | 1/31 |
| TonsillitisInfections and infestations | 1/108 | 0/108 | 0/111 | 0/67 | 0/79 | 0/295 | 1/440 | 0/171 | 0/129 | 2/203 | 3/197 | 2/199 | 0/122 | 5/125 | 0/75 | 2/23 | 0/31 |
| HeadacheNervous system disorders | 8/108 | 3/108 | 6/111 | 2/67 | 3/79 | 8/295 | 13/440 | 1/171 | 0/129 | 12/203 | 8/197 | 9/199 | 8/122 | 5/125 | 3/75 | 2/23 | 0/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/108 | 2/108 | 4/111 | 1/67 | 1/79 | 6/295 | 7/440 | 2/171 | 2/129 | 13/203 | 12/197 | 16/199 | 5/122 | 5/125 | 1/75 | 1/23 | 1/31 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/108 | 1/108 | 1/111 | 3/67 | 0/79 | 1/295 | 5/440 | 2/171 | 1/129 | 8/203 | 6/197 | 15/199 | 2/122 | 5/125 | 2/75 | 0/23 | 1/31 |
| NasopharyngitisInfections and infestations | 2/108 | 0/108 | 1/111 | 0/67 | 0/79 | 8/295 | 6/440 | 5/171 | 3/129 | 10/203 | 8/197 | 7/199 | 9/122 | 7/125 | 3/75 | 0/23 | 1/31 |
| PyrexiaGeneral disorders | 5/108 | 2/108 | 1/111 | 1/67 | 2/79 | 3/295 | 8/440 | 1/171 | 1/129 | 6/203 | 7/197 | 9/199 | 4/122 | 8/125 | 1/75 | 1/23 | 1/31 |
Full analysis set (FAS) which included all randomized participants (in IS-1 and IS-2) with a modified Mayo score (MMS) of 5 to 9 who received at least 1 (partial or complete) dose of study intervention.
| Age, Continuous(Years) | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | Total |
|---|---|---|---|---|---|---|
| Mean | 41.2 ± 15.05 | 43.3 ± 14.28 | 40.4 ± 13.84 | 39.8 ± 13.43 | 41 ± 13.9 | 40.9 ± 13.93 |
| Sex: Female, Male(Participants) | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | Total |
|---|---|---|---|---|---|---|
| Female | 39 | 41 | 48 | 119 | 183 | 430 |
| Male | 66 | 60 | 59 | 161 | 238 | 584 |
| Ethnicity (NIH/OMB)(Participants) | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 4 | 21 | 25 | 59 |
| Not Hispanic or Latino | 97 | 92 | 98 | 240 | 368 | 895 |
| Unknown or Not Reported | 4 | 4 | 5 | 19 | 28 | 60 |
| Race (NIH/OMB)(Participants) | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 24 | 23 | 27 | 62 | 88 | 224 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 1 | 3 | 4 | 10 |
| White | 77 | 73 | 74 | 205 | 304 | 733 |
| More than one race | 0 | 1 | 0 | 0 | 1 | 2 |
| Unknown or Not Reported | 3 | 3 | 5 | 10 | 22 | 43 |
| Region of Enrollment(Participants) | IS-1: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | IS-1: Period 1: Guselkumab 400 mg IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Placebo IV at Weeks I-0, I-4 and I-8 | IS-2: Period 1: Guselkumab 200 mg IV at Weeks I-0, I-4 and I-8 | Total |
|---|---|---|---|---|---|---|
| Argentina | 0 | 0 | 2 | 5 | 10 | 17 |
| Australia | 2 | 1 | 2 | 7 | 14 | 26 |
| Belgium | 1 | 0 | 0 | 3 | 3 | 7 |
| Brazil | 0 | 2 | 0 | 12 | 15 | 29 |
| Bulgaria | 1 | 0 | 1 | 2 | 3 | 7 |
| Canada | 0 | 0 | 0 | 2 | 5 | 7 |
| China | 7 | 2 | 2 | 26 | 35 | 72 |
| Czech Republic | 1 | 2 | 1 | 11 | 17 | 32 |
| France | 5 | 10 | 6 | 10 | 30 | 61 |
| Germany | 3 | 3 | 3 | 11 | 8 | 28 |
| Hungary | 4 | 5 | 3 | 11 | 17 | 40 |
| Ireland | 0 | 0 | 0 | 1 | 0 | 1 |
| Israel | 0 | 1 | 1 | 5 | 7 | 14 |
| Italy | 5 | 2 | 6 | 14 | 15 | 42 |
| Japan | 9 | 12 | 15 | 25 | 33 | 94 |
| Jordan | 0 | 0 | 0 | 16 | 18 | 34 |
| Latvia | 0 | 0 | 0 | 5 | 3 | 8 |
| Malaysia | 0 | 0 | 0 | 3 | 4 | 7 |
| New Zealand | 0 | 0 | 1 | 2 | 5 | 8 |
| Poland | 19 | 22 | 24 | 47 | 71 | 183 |
| Portugal | 2 | 2 | 1 | 1 | 0 | 6 |
| Russian Federation | 9 | 7 | 6 | 18 | 20 | 60 |
| Serbia | 0 | 0 | 0 | 5 | 5 | 10 |
| Slovakia | 0 | 0 | 0 | 2 | 12 | 14 |
| South Korea | 6 | 7 | 5 | 2 | 11 | 31 |
| Spain | 2 | 1 | 1 | 2 | 2 | 8 |
| Sweden | 2 | 1 | 0 | 0 | 3 | 6 |
| Taiwan | 2 | 1 | 3 | 2 | 1 | 9 |
| Turkey | 0 | 0 | 2 | 3 | 11 | 16 |
| Ukraine | 16 | 16 | 14 | 13 | 20 | 79 |
| United Kingdom | 3 | 1 | 1 | 3 | 6 | 14 |
| United States | 6 | 3 | 7 | 11 | 17 | 44 |
Showing the first 100 of 392 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2019 to primary completion in Sep 2023, 47 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →